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Real time qPCRDuring the last decade, the area of non-invasive prenatal diagnosis (NIPD) has rapidly evolved. Several meth-
odological approaches have been presented and demonstrated a proof of concept for the NIPD of chromo-
somal aneuploidies. The two most promising methods are NIPD using next generation sequencing
technologies and NIPD using Methylation DNA Immunoprecipitation (MeDIP) with real time qPCR. Both ap-
proaches have been validated with blind studies and have >99% accuracy. NIPD using next generation se-
quencing is achieved by high throughput shotgun sequencing of DNA from plasma of maternal women
followed by ratio comparisons of each chromosome sequence tag density over the median tag density of
all autosomes (z-score analysis). The MeDIP real time qPCR method, which is described in this review in
more detail, is based on the identiﬁcation of differentially methylated regions (DMRs) and their use in dis-
criminating normal from abnormal cases. More than 10,000 DMRs were identiﬁed for chromosomes 13, 18,
21, X and Y using high resolution oligo-arrays that can be potentially used for the NIPD of aneuploidies for
chromosomes 13, 18, 21, X and Y. Both NIPD methods have several advantages and limitations and it is be-
lieved that they will soon be implemented in clinical practice. With the continuous advancements of genetic
methodologies and technologies, we predict that within the next 10 years we will be able to provide NIPD for
all common and rare genetic disorders where the molecular basis is known.
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Non-invasive prenatal diagnosis (NIPD) is one of the most fasci-
nating research areas in molecular medicine of the last decade. Theis; cffDNA, cell free fetal DNA;
uantitative PCR; DMRs, differ-
pling; SNP, single nucleotide
-NC-ND license. medical signiﬁcance of the development of NIPD is of great impor-
tance as it can potentially be offered to all pregnancies, presents no
risk of loss of the pregnancy and provides a more effective prenatal
diagnosis compared to currently used invasive methods.
The identiﬁcation and isolation of fetal DNA by non-invasive means,
which will then be analyzed using molecular methodologies, are the
key issue toward NIPD. The ﬁrst evidence for circulating nucleic acids
in the peripheral blood was shown by Mandel and Métals (1948). The
isolation in 1997 of fetal cells from maternal blood (Bianchi et al.,
1997) and the identiﬁcation of small amounts of cell free fetal DNA in
maternal plasma (cffDNA) (Lo et al., 1997) have greatly facilitated the
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(Lo et al., 1998), as well as the fact that it is 50% identical and co-exists
withmaternal DNA, posesmajor challenges toward the development of
NIPD.
2. Toward NIPD for genetic disorders
NIPD was initially attempted using the strategy of the isolation of in-
tact fetal cells from maternal blood using ﬂuorescence in situ hybridiza-
tion (FISH) and other molecular analyses (Hassold et al., 1996).
However, the very small number of fetal cells (1 in 350,000 maternal
cells) (Hamada et al., 1993) and the isolation of these cells, present
major difﬁculties toward achieving this goal. Alternatively, a more feasi-
ble approach for the development of NIPDwas to use the relatively abun-
dant cffDNA present in maternal circulation. Initially NIPD was achieved
for genetic loci of absolute fetal speciﬁcity, such as Y-chromosome specif-
ic markers (Lo et al., 1998) and the fetal RhD gene (Faas et al., 1998).
Therefore, the development of NIPD for the diagnosis of X-linked disor-
ders (Anon, 2007) and rhesus D positive fetuses (Wright and Burton,
2009) was relatively straightforward and very accurate. However, the
development of NIPD for genetic loci of non-absolute fetal speciﬁcity,
such as autosomal fetal DNA aneuploidies for chromosomes 13, 18, 21,
X and Y proved much more challenging (Chim et al., 2005; Tsui et al.,
2010; Tong et al., 2010a). This has mainly been achieved using sodium
bisulphate conversion and/or methylation sensitive restriction enzymes
with conventional, as well as digital PCR methods (Lo et al., 2007a; Fan
and Quake, 2007).
The most promising demonstrations of NIPD were based on the
use of differentially methylated markers (DMRs), which have differ-
ences in their methylation status between fetal DNA and maternal
DNA (Chim et al., 2005; Tsui et al., 2010; Tong et al., 2010a; Poon
et al., 2002; Old et al., 2007; Lo et al., 2007b; Chim et al., 2008). Sev-
eral studies used DMRs in combination with informative SNPs and
methylation sensitive restriction enzymes and/or sodium bisulphate
conversion methods (Tsui et al., 2010; Tong et al., 2010a,b). These
methods were compromised by the limited number of known
DMRs, and the even more limited number of informative SNPs or
methylation sensitive sites in these regions. In addition, complete so-
dium bisulphate conversion is rarely achieved and degradation of
DNA always occurs after sodium bisulphate treatment. These limita-
tions compromised the accuracy and thus the diagnostic usefulness
of these NIPD methods. To overcome the above limitations, our
team aimed in identifying a very high number of DMRs of high qual-
ity, as well as in developing a new NIPD approach for genetic disor-
ders (Papageorgiou et al., 2009, 2011).
3. NIPD of Down syndrome using MeDIP and real time qPCR
The identiﬁcation of newDMRs on chromosomes 13, 18, 21, X and Y
was achieved by using a method consisting of methylated DNA immu-
noprecipitation with high resolution oligo-arrays (MeDiP on a Chip)
(Papageorgiou et al., 2009; Rakyan et al., 2008), and is shown in Fig. 1.
In principle, DNA from non-pregnant female blood and 1st and 3rd
trimester placentas were immunoprecipitated in two separate experi-
ments, using a speciﬁc antibody for CG-methyl sites. The isolated hyper-
methylated regions (MeDiP DNA) and non-hypermethylated regions
(input DNA) of female blood and placenta samples were co-
hybridized on a high resolution oligo-array. The microarray platform
was a high resolution oligo-array of chromosomes 13, 18, 21, X and Y.
Differentially methylated regions were identiﬁed using the SW-
ARRAY algorithm previously used for copy number variation (CNV)
calling, as described by Price et al. (2005). As a result, more than
10,000 candidate DMRs were isolated (Papageorgiou et al., 2009). This
study provided numerous DMRs that could be potentially used for
NIPD of aneuploidies of chromosomes 13, 18, 21, X and Y.Among the ~2,000 DMRs identiﬁed on chromosome 21, the most
suitable 12 DMRs of chromosome21were selected based on the follow-
ing three criteria: ﬁrstly, the region should be hypermethylated in the
placenta and hypomethylated in the maternal peripheral blood; sec-
ondly, the methylation status should be the same in the ﬁrst and third
trimester placentas; and thirdly the methylation level should be above
a certain threshold value determined from microarray analysis. The
methylation levels of all 12 of these selected DMRs on chromosome
21 were re-conﬁrmed by real time qPCR using peripheral blood of
non-pregnant women as well as 1st and 3rd trimester placentas from
individuals not screened in the initial microarray experiments. This
work veriﬁed that these 12DMRs consistently showedhypomethylation
in peripheral blood andhypermethylation in placentas (Papageorgiou et
al., 2009) and also showed that the degree of methylation varied
between individuals, an observation which is called interindividual
methylation.
In order to demonstrate that theseDMRs can be used to identify fetal
DNA in maternal peripheral blood and discriminate normal from Down
syndrome cases, several samples of peripheral blood from normal as
well as trisomy 21 pregnancies were tested and analyzed. Fig. 2 demon-
strates the ratio value calculation of a Down syndrome or a normal case
compared to the median value of normal control cases. These results,
and statistical analysis of the ratio value differences between normal
and abnormal cases, permitted the development of a new NIPD for tri-
somy 21 which is based on measuring and comparing fetal speciﬁc
methylation ratios between unknown and known normal pregnancies
(Fig. 2).
This newly developed NIPDmethod for trisomy 21 usingMeDIP and
real time qPCR was initially tested in 40 maternal peripheral bloods, of
which 20were from normal and 20 from Down syndrome pregnancies.
A combination of results obtained from 8 out of 12 DMRs tested led to
the correct diagnosis of all 20 normal and 20 Down syndrome pregnan-
cies tested (Papageorgiou et al., 2011). The method involves MeDIP of
known normal and unknown DNAs, freshly extracted from peripheral
blood at 11–13 weeks of gestation, real time qPCR of eight DMRs and
statistical analysis using a diagnostic equation (Papageorgiou et al.,
2011) (Fig. 2). The new NIPD method was further validated in a
blind study with 40 additional maternal peripheral blood samples,
26 of which were women bearing a normal fetus and 14 bearing a
Down syndrome fetus. Prediction values obtained from normal and
trisomy 21 cases demonstrated the correct diagnosis of all samples,
providing 100% speciﬁcity and 100% sensitivity (Papageorgiou et
al., 2011).
4. NIPD in clinical practice
Currently, two methods have been developed and validated, and
have demonstrated a near 100% accuracy. One method is based on
next generation sequencing (Fan et al., 2008; Chiu et al., 2008), and
the other one is based on MeDIP and real time qPCR (Papageorgiou
et al., 2009, 2011). NIPD by next generation sequencing is achieved
by high throughput shotgun sequencing of DNA from plasma of ma-
ternal peripheral blood, followed by ratio analysis of each chromo-
some sequence tag density over the median tag density of all
autosomes using a z-score analysis (Fan et al., 2008). The method
was further validated using 753 plasma samples of which 86 were
from Down syndrome pregnancies and provided 100% and 97.9%,
sensitivity and speciﬁcity, respectively (Chiu et al., 2011). Recently,
an additional validation study using next generation sequencing
was carried out in 1696 cases and demonstrated 98.6% and 99.8%,
sensitivity and speciﬁcity, respectively (Palomaki et al., 2011). The
MeDIP and real time qPCR based approach (Papageorgiou et al.,
2009, 2011), was developed and validated using 80 samples of mater-
nal peripheral blood, from 46 women bearing a normal fetus and 34
bearing a Down syndrome fetus, and provided 100% speciﬁcity and
100% sensitivity (Papageorgiou et al., 2011). Recently, a larger cohort
Fig. 1. Identiﬁcation of DMRs using MeDIP on a Chip. (a) Extracted DNA placenta sample and DNA female blood non-pregnant sample were immunoprecipitated (MeDIP) using an
antibody targeting 5-methylcytocines of CG dinucleotides. An aliquot of unprocessed DNA (Input DNA) was not immunoprecipitated. MeDIP DNA and Input DNA were then co-
hybridized on high resolution oligo-arrays speciﬁc for chromosomes 13, 18, 21, X and Y with median probe spacing of 225 bp, 170 bp, 70 bp, 340 bp and 20 bp, respectively. Dif-
ferentially methylated regions (DMRs) in non-pregnant female blood and placental DNAs were identiﬁed and ratio differences between them were calculated. (b) The plot shows
the methylation levels in a region of chromosome 21. The red circle shows an informative DMR region because it is hypomethylated in DNA from peripheral blood of non-pregnant
women and hypermethylated in DNA from 1st and 3rd trimester placentas. The methylation difference between peripheral blood and placenta is signiﬁcant.
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the same level of accuracy (Tsaliki et al., submitted for publication).
However, prior to considering the method ready for implementation
in clinical practice, an even larger validation study consisting of
1000 samples will soon be initiated.Comparison between the two methods shows several similarities.
They are both considered accurate, with sensitivity and speciﬁcity
close to 99% (Verweij et al., 2012). Both methods can be offered as
early as the 10th week of gestation and can yield rapid results, with
a higher turn-over time of 15–21 days for NIPD using next generation
Fig. 2. Fetal speciﬁc DNAmethylation ration permits NIPD of Down syndrome. DNA from peripheral blood of known normal and unknown pregnancies are ﬁrst immunoprecipitated
using the MeDIP protocol to enrich fetal DNA in regions (DMRs) that are known to be hypermethylated in the fetus and hypomethylated in the mother. Real time qPCR is used to
quantify all DMRs on chromosome 21 and measures the fetal speciﬁc DNA methylation ratio between the test sample (Down syndrome in this ﬁgure) and a median of known nor-
mal samples. A D value is derived using the ratios from several DMRs and provides the ﬁnal result of the test sample (Down syndrome in this ﬁgure). F: fetal, M: maternal, red dots:
hypermethylated DNA, and black dots: hypomethylated DNA.
6 P.C. Patsalis / Applied & Translational Genomics 1 (2012) 3–8sequencing compared to a lower turn-over time of 2–3 days for NIPD
using MeDIP and real time qPCR. As stated earlier, the NIPD method
using next generation sequencing has been validated using a larger
number of samples and thus, has been more extensively proven to
be accurate and robust and is therefore expected to be implemented
in clinical practice ﬁrst. The NIPD method using MeDIP and real
time qPCR will soon undergo additional validation with a cohort of
1000 samples, which is necessary prior to clinical implementation.
Such large validation studies will further improve and reﬁne the sta-
tistical analysis and, more importantly, identify additional parameters
that may inﬂuence the results that lead to false positive or false neg-
ative misdiagnosis. In regard to their cost and complexity, NIPD using
next generation sequencing is currently more expensive (~1900 USD)
and more complex as it requires specialized or complex laboratory
equipment, software, infrastructure or know-how, while NIPD using
MeDIP and real time qPCR is considerably less expensive (~400
Euros) and is less complex as it uses standard molecular biology tech-
niques and infrastructure.
5. NIPD of genetic disorders in the years to come
Since the 1970s, prenatal diagnosis has been offered through the
invasive procedures of CVS, amniocentesis and chordocentesis using
chromosomal analysis, FISH and DNA methods (Fig. 3). With the
rapid advances in technologies and methodologies, the scientiﬁc
community has managed to increase the resolution of genome analy-
sis. Such achievements permitted the detection of DNA defects fromthe size of megabases to single bases. These advances led from the
karyotype and the detection of aneuploidies, to FISH and the identiﬁ-
cation of common microdeletion and subtelomeric rearrangements,
to array CGH and identiﬁcation of causative copy number changes,
and currently to DNA molecular analyses and the identiﬁcation of
causative point mutations. It took us 50 years to move from the use
of invasive prenatal diagnosis for chromosome analysis to the very
high resolution genomic analyses and consequently this has led to
the provision of prenatal diagnosis of an increasingly greater number
of genetic disorders, as well as in signiﬁcant improvements in accura-
cy (i.e. “more and better”) (Fig. 3).
For the last 20 years to make NIPD a reality has been the goal of sev-
eral groups (Fig. 3). It appears that ﬁnally, now in 2012, a new era of
non-invasive prenatal diagnosis has begun. Before the end of this year
we will be ready to provide NIPD of Down syndrome and very soon
after, NIPD for other aneuploidies. The rapid advancements in method-
ologies such as MeDIP and real time qPCR, next generation sequencing,
digital PCR, array-CGH and other emerging technologies will permit
within the next 10 years, provision of NIPD for all other common and
rare genetic disorders. Therefore, the continuous development and im-
provement of NIPDmethodologieswill not only providemore andhigh-
ly accurate prenatal diagnosis of genetic disorders (“more and better”),
but will do so without any risk for the fetus. It will therefore be a more
effective approach for prenatal diagnosis which may be offered to all
pregnant women regardless of age or indication.(i.e. “safe, effective
and holistic”) (Fig. 3). By the year 2020, NIPD will be a reality for the
testing of the most common and rare genetic disorders.
Fig. 3. From chromosomes to high resolution DNA analysis and from invasive to non-invasive prenatal diagnosis.
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